IP Verse

Etherna Immunotherapies patent opposition analysis

Get complete Patent Opposition Report for Etherna Immunotherapies

Comprehensive Analysis, Strategic Insights & Expert Evaluation – Stay Ahead in Your Patent Challenge.

Latest oppositions filed by Etherna Immunotherapies

Explore patent oppositions filed by Etherna Immunotherapies against competitors, revealing strategic technology disputes and market positioning. Monitor opposition details, timelines, and disputed innovations to understand competitive dynamics and IP enforcement strategy.

Patent Number	Title	Applicant	Opposition Date
EP3283059	Method For Producing Rna Compositions	CUREVAC	Oct 3, 2024
EP3590949	Ribonucleic Acids Containing N1-Methyl-Pseudouracils And Uses Thereof	MODERNATX	Feb 20, 2023
EP2791160	Modified Nucleoside, Nucleotide, And Nucleic Acid Compositions	MODERNA THERAPEUTICS	Dec 2, 2022
EP3682905	Modified Nucleosides, Nucleotides, And Nucleic Acids, And Uses Thereof	MODERNATX	Aug 31, 2022
EP3173092	Rna Containing Composition For Treatment Of Tumor Diseases	CUREVAC	Mar 26, 2020
EP3153179	Optimised Injection Formulation For Mrna	CUREVAC	Mar 18, 2020
EP3292873	Combination Of Vaccination And Inhibition Of The Pd-1 Pathway	CUREVAC	Feb 3, 2020
EP2216028	Immunostimulation By Chemically Modified Rna	CUREVAC	Sep 6, 2018
EP2958588	Combination Of Vaccination And Inhibition Of The Pd-1 Pathway	CUREVAC	May 23, 2018

Top competitors of Etherna Immunotherapies

CUREVAC

MODERNATX

CUREVAC MANUFACTURING